Next Generation Sequencing allows identification of new mutations related to lung cancer
October 2017
Icahn School of Medicine at Mount Sinai, New York, USA
Lung cancer remains the most prevalent cancer and the leading cause of cancer mortality. Genetic and genomic profiling in lung cancers has not only facilitated the understanding of the molecular mechanisms of pathogenesis but also significantly impacted clinical practice. In the USA, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommend genetic testing for seven genes (EGFR, ALK, ROS1, RET, BRAF, MET, HER2) with available targeted therapies. In the present study, the researchers analyzed by Next Generation Sequencing a total of 932 lung cancer patients samples to detect various mutations in 50 cancer-related genes. The goal of the study was to expand the landscape of genetic mutations (i.e. not yet included in the NCCN guideline) that could inform clinical decisions. Results allowed identification of activating mutations in additional genes JAK2 and JAK3 with clinical implications. The study concludes that Next Generation Sequencing should allow better clinical decisions.
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
Fei Ye, Rong Chen
Added on: 09-17-2021
[1] https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0478-1[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
